AUSTRALIAN CLINICAL LABS LIMITED (ACL)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

ACL - AUSTRALIAN CLINICAL LABS LIMITED
FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.77
Index: ASX300 | ALL-ORDS
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$2.83
25 Sep |
OPEN $2.81 |
HIGH $2.86 |
338,010 LOW $2.75 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 100% |
OTHER COMPANIES IN THE SAME SECTOR | |||
AHX . ALC . BMT . CAJ . DOC . EBO . HLA . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | 17.9 | 18.0 | xxx |
DPS (cps) | xxx | 14.0 | 13.2 | xxx |
EPS Growth | xxx | - 79.8% | 0.7% | xxx |
DPS Growth | xxx | - 73.6% | - 6.0% | xxx |
PE Ratio | xxx | N/A | 15.7 | xxx |
Dividend Yield | xxx | N/A | 4.7% | xxx |
Div Pay Ratio(%) | xxx | 78.2% | 73.0% | xxx |
Last ex-div: 14/09 - ex-div 7c (franking 100%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | 17.9 |
DPS All | xxx | xxx | xxx | xxx | 14.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | 692.1 M |
Book Value Per Share | xxx | xxx | xxx | xxx | 86.0 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | 143.7 M |
Net Profit Margin | xxx | xxx | xxx | xxx | 5.19 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | 17.73 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | 9.12 % |
Return on Assets | xxx | xxx | xxx | xxx | 5.95 % |
Return on Equity | xxx | xxx | xxx | xxx | 17.73 % |
Return on Total Capital | xxx | xxx | xxx | xxx | 11.40 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | 39.9 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | 101 M |
Long Term Debt | xxx | xxx | xxx | xxx | 215 M |
Total Debt | xxx | xxx | xxx | xxx | 316 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | 159 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | 21 M |
Price To Book Value | xxx | xxx | xxx | xxx | 4.00 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | 6.9 M |
Capex % of Sales | xxx | xxx | xxx | xxx | 1.00 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | 546 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | 90 M |
Research & Development | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
ACL STOCK CHART

FNArena News on ACL
1 |
Rudi’s View: Outlook Negative, With Plenty Of Silver LiningsSep 06 2023 - Rudi's View |
2 |
Australian Broker Call *Extra* Edition – Aug 24, 2023Aug 24 2023 - Daily Market Reports |
3 |
FNArena Corporate Results Monitor – 23-08-2023Aug 23 2023 - Australia |
4 |
Rudi’s View: Awaiting The August VerdictAug 02 2023 - Rudi's View |
5 |
Australian Broker Call *Extra* Edition – Jul 25, 2023Jul 25 2023 - Daily Market Reports |
Latest Healthcare services News
1 |
Timing Seems Right For Alcidion GroupJun 21 2023 - Small Caps |
2 |
No Enthusiasm To Combine ACL & HealiusMar 21 2023 - Australia |
3 |
Dr Boreham’s Crucible: AlcidionDec 13 2022 - Small Caps |
4 |
No Straight Covid-Relief For Ramsay Health CareNov 15 2022 - Australia |
5 |
Dr Boreham’s Crucible: Mach7 TechnologiesNov 14 2022 - Small Caps |
6 |
Negative Industry Trends Impact Australian Clinical LabsAug 12 2022 - Small Caps |
7 |
Healius Offers Digital Carrot, Base Remains SoftMay 25 2022 - Australia |
8 |
Ramsay Stakes Future on Mental HealthDec 20 2021 - Australia |
9 |
Ramsay Health Care: Finally A Break-OutNov 09 2021 - Technicals |
10 |
Funding Overhang Weighs On Ramsay’s ReboundJun 10 2021 - Australia |